Incidence of all-cause and cardiovascular mortality predicted by symmetric dimethylarginine in the population-based Study of Health in Pomerania

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Schwedhelm, Edzard ^a,b   Wallaschofski, Henri ^b,c   Atzler, Dorothee ^a,b   Dörr, Marcus ^b,c   Nauck, Matthias ^b,c   Völker, Uwe ^b,c   Kroemer, Heyo K ^b   Völzke, Henry ^b,c   Böger, Rainer H ^a,b   Friedrich, Nele ^b,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 N,N' DIMETHYLARGININE; ARGININE; N(G),N(G) DIMETHYLARGININE; N,N'-DIMETHYLARGININE; N,N-DIMETHYLARGININE;

ADULT; AGED; ALL CAUSE MORTALITY; AMINO ACID BLOOD LEVEL; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; FEMALE; HEART DEATH; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PROGNOSIS; RISK ASSESSMENT; SURVIVAL TIME; VERY ELDERLY; YOUNG ADULT; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASE; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ARGININE; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84901274691     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096875     Document Type: Article

References (28)

1. Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C (2012) The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 10: 4-18.
2. Servillo L, Giovane A, Cautela D, Castaldo D, Balestrieri ML (2013) The methylarginines NMMA, ADMA, and SDMA are ubiquitous constituents of the main vegetables of human nutrition. Nitric Oxide 30: 43-48.
3. Böger RH (2007) The pharmacodynamics of L-arginine. J Nutr 137: 1650S-1655S.
4. Schwedhelm E, Maas R, Freese R, Jung D, Lukacs Z, et al. (2008) Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol 65:51-59. (Pubitemid 350265175)
5. Vallance P, Leone A, Calver A, Collier J, Moncada S (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575.
6. Closs EI, Basha FZ, Habermeier A, Förstermann U (1997) Interference of L-arginine analogues with L-arginine transport mediated by the y + carrier hCAT-2B. Nitric Oxide 1: 65-73. (Pubitemid 28078129)
7. Strobel J, Mieth M, Endress B, Auge D, König J, et al. (2012) Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1). Journal of molecular and cellular cardiology 53:392-400.
8. Böger RH (2006) Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 38: 126-136.
9. Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, et al. (2009) Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 119: 1592-1600.
10. Gore MO, Lüneburg N, Schwedhelm E, Ayers CR, Anderssohn M, et al. (2013) Symmetric dimethylarginine predicts mortality in the general population. Arterioscler Thromb Vasc Biol 33: 2682-8.
11. John U, Greiner B, Hensel E, Lüdemann J, Piek M, et al. (2001) Study of Health In Pomerania (SHIP): a health examination survey in an east German region: objectives and design. Soz Praventivmed 46: 186-194. (Pubitemid 32747278)
12. Völzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, et al. (2011) Cohort Profile: The Study of Health in Pomerania. Int J Epidemiol 40: 294-307.
13. Keil U, Stieber J, Döring A, Chambless L, Härtel U, et al. (1988) The cardiovascular risk factor profile in the study area Augsburg. Results from the first MONICA survey 1984/85. Acta Med Scand Suppl 728: 119-128. (Pubitemid 19047660)
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470. (Pubitemid 29135798)
15. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, et al. (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139: 137-147.
16. Atzler D, Mieth M, Maas R, Böger RH, Schwedhelm E (2011) Stable isotope dilution assay for liquid chromatography-tandem mass spectrometric determination of L-homoarginine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 879: 2294-2298.
17. Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, et al. (2007) High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 851: 211-219. (Pubitemid 46720141)
18. Stone C, Koo CY (1985) Additive splines in statistics. Washington, DC: American Statistcal Association.
19. Pencina MJ, D'Agostino RB (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 23: 2109-2123.
20. Caplin B, Leiper J (2012) Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators? Arterioscler Thromb Vasc Biol 32: 1343-1353.
21. Schepers E, Glorieux G, Dhondt A, Leybaert L, Vanholder R (2009) Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant 24: 1429-1435.
22. Kiechl S, Lee T, Santer P, Thompson G, Tsimikas S, et al. (2009) Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population. Atherosclerosis 205: 261-265.
23. Meinitzer A, Kielstein JT, Pilz S, Drechsler C, Ritz E, et al. (2011) Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem;57: 112-121.
24. Siegerink B, Maas R, Vossen CY, Schwedhelm E, Koenig W, et al. (2013) Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study. Clin Res Cardiol 102: 193-202.
25. Seppälä I, Kleber ME, Lyytikäinen LP, Hernesniemi JA, Mäkelä KM, et al. (2014) Genome-wide association study on dimethylarginines reveals novel AGXT2 variants associated with heart rate variability but not with overall mortality. Eur Heart J. 35: 524-531.
26. Schwedhelm E, Böger RH (2011) The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol 7: 275-285.
27. Ronden RA, Houben AJ, Teerlink T, Bakker JA, Bierau J, et al. (2012) Reduced renal plasma clearance does not explain increased plasma asymmetric dimethylarginine in hypertensive subjects with mild to moderate renal insufficiency. Am J Physiol Renal Physiol 303: F149-156.
28. Kielstein JT, Salpeter SR, Bode-Böger SM, Cooke JP, Fliser D (2006) Symmetric dimethylarginine (SDMA) as endogenous marker of renal function - a meta-analysis. Nephrol Dial Transplant 21: 2446-2451. (Pubitemid 44644516)